Editas Medicine Inc (NASDAQ: EDIT) kicked off on Tuesday, up 17.29% from the previous trading day, before settling in for the closing price of $1.33. Over the past 52 weeks, EDIT has traded in a range of $0.91-$6.69.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Over the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 96.99%. While this was happening, its average annual earnings per share was recorded 49.07%. With a float of $82.93 million, this company’s outstanding shares have now reached $83.71 million.
Considering the fact that the conglomerate employs 246 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is 86.3%, operating margin of -777.25%, and the pretax margin is -733.74%.
Editas Medicine Inc (EDIT) Insider Activity
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Editas Medicine Inc is 0.93%, while institutional ownership is 62.10%. The most recent insider transaction that took place on Mar 04 ’25, was worth 7,030. In this transaction EVP, CHIEF FINANCIAL OFFICER of this company sold 4,109 shares at a rate of $1.71, taking the stock ownership to the 112,720 shares. Before that another transaction happened on Mar 04 ’25, when Company’s CEO sold 16,632 for $1.71, making the entire transaction worth $28,452. This insider now owns 295,474 shares in total.
Editas Medicine Inc (EDIT) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.42 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 49.07% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 23.95% during the next five years compared to -1.48% drop over the previous five years of trading.
Editas Medicine Inc (NASDAQ: EDIT) Trading Performance Indicators
Take a look at Editas Medicine Inc’s (EDIT) current performance indicators. Last quarter, stock had a quick ratio of 3.75. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 4.04.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.88, a number that is poised to hit -0.56 in the next quarter and is forecasted to reach -1.05 in one year’s time.
Technical Analysis of Editas Medicine Inc (EDIT)
Compared to the last year’s volume of 3.56 million, its volume of 1.84 million showed lagged in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 80.45%. Additionally, its Average True Range was 0.15.
During the past 100 days, Editas Medicine Inc’s (EDIT) raw stochastic average was set at 27.20%, which indicates a significant decrease from 97.01% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 125.52% in the past 14 days, which was lower than the 162.55% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.4717, while its 200-day Moving Average is $2.6712. Nevertheless, the first resistance level for the watch stands at $1.6333 in the near term. At $1.7067, the stock is likely to face the second major resistance level. The third major resistance level sits at $1.8333. If the price goes on to break the first support level at $1.4333, it is likely to go to the next support level at $1.3067. Should the price break the second support level, the third support level stands at $1.2333.
Editas Medicine Inc (NASDAQ: EDIT) Key Stats
The company with the Market Capitalisation of 130.58 million has total of 83,710K Shares Outstanding. Its annual sales at the moment are 32,310 K in contrast with the sum of -237,090 K annual income. Company’s last quarter sales were recorded 30,610 K and last quarter income was -45,390 K.
